Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HER2 antibody conjugated natural killer cells ACE1702

An off-the-shelf preparation of natural killer (NK) cells conjugated to a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), with potential antineoplastic activity. Upon administration of anti-HER2 antibody conjugated natural killer cells ACE1702, the antibody moiety targets and binds to HER2 on tumor cells, which may lead to cell lysis of HER2-expressing tumor cells by the NK cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-HER2 antibody conjugated NK cells ACE1702
anti-HER2 antibody natural killer cell conjugate ACE1702
anti-HER2 conjugated NK cells ACE1702
anti-HER2 NK cells
anti-HER2 NK cells ACE1702
Code name:ACE 1702
ACE-1702
ACE1702
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search